The Wall Street Journal reports biotech analysts are receiving lucrative pay packages as a result of the boom in biotech investment banking activity, including IPOs, equity offerings and M&A. Top analysts are getting remuneration in the $3M – 4M range because of their value in backing banking deals (a major source of conflicted interest in the dot-com crash in 2000).
